Neuropace
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $27,354 | $23,520 | $22,524 | $21,466 |
Gross Profit | 21,168 | 18,132 | 17,342 | 16,188 |
EBITDA | -2,464 | -6,115 | -3,974 | -2,607 |
EBIT | -2,518 | -6,592 | -4,436 | -3,058 |
Net Income | -3,496 | -8,651 | -6,589 | -5,250 |
Net Change In Cash | 27,354 | 23,520 | 22,524 | 21,466 |
Free Cash Flow | -1,974 | -2,254 | -7,519 | -4,836 |
Cash | 20,648 | 22,857 | 27,019 | 13,430 |
Basic Shares | 33,134 | 32,863 | 31,480 | 29,914 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $79,906 | $65,421 | $45,520 | $45,183 |
Gross Profit | 59,085 | 48,122 | 32,493 | 33,435 |
EBITDA | -16,574 | -22,834 | -36,566 | -28,374 |
EBIT | -18,343 | -24,439 | -39,553 | -28,670 |
Net Income | -27,141 | -32,956 | -47,082 | -36,080 |
Net Change In Cash | 79,906 | 65,421 | 45,520 | 45,183 |
Cost of Revenue | -12,582 | -7,447 | ||
Free Cash Flow | -18,255 | -19,874 | -37,472 | -24,961 |
Cash | 13,430 | 18,058 | 6,605 | 19,187 |
Basic Shares | 29,126 | 25,851 | 24,594 | 16,608 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.11 |
2025-06-30 | -$0.26 |
2025-03-31 | -$0.21 |
